Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 2

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 2
Chunk 2
---
99 495—950.06 Restructuring and restructuring-related net charges (credits)36 630—300.02 Investment portfolio net losses (gains) and impairments(6)(1)(5)—(5)(0.00)European Union (EU) Medical device regulation (MDR) implementation costs11 29—90.01 Deferred tax expenses (benefits)— (47)47—470.03 Discrete tax items— (1)1—10.00 Adjusted$1,303 $177 $1,126 $2 $1,124 $0.75 

 Three Months Ended September 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$669 $200 $468 $(0)$469 $0.32 Non-GAAP adjustments:Amortization expense205 28 177 2 175 0.12 Acquisition/divestiture-related net charges (credits)144 (56)200 — 200 0.13 Restructuring and restructuring-related net charges (credits)52 7 45 — 45 0.03 Investment portfolio net losses (gains) and impairments(1)0 (1)— (1)(0.00)EU MDR implementation costs13 2 12 — 12 0.01 Deferred tax expenses (benefits)— (38)38 — 38 0.03 Adjusted$1,082 $143 $939 $2 $937 $0.63 

41

Table of Contents

Nine Months Ended September 30, 2025

Our net sales for the first nine months of 2025 were $14.788 billion, compared to $12.186 billion for the first nine months of 2024. This increase of $2.602 billion, or 21.4 percent, included operational1 net sales growth of 21.0 percent and the positive impact of 30 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 16.9 percent and the positive impact of 410 basis points from